Panacea Biotec , a prominent player in the Indian pharmaceutical sector, has reported its financial results for the second quarter, revealing a significant increase in net loss and a decline in revenue.

Financial Performance Overview

Key Highlights

• Widened Net Loss: Panacea Biotec's consolidated net loss for the quarter increased to ₹139.00 million, nearly tripling from ₹48.00 million in the same period last year.

• Revenue Decline: The company experienced a year-over-year revenue decline, with Q2 revenue dropping to ₹1.40 billion from ₹1.47 billion in the previous year.

• EBITDA Deterioration: The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) shifted from a positive ₹70.00 million in the prior year's quarter to a loss of ₹178.00 million.

Operational Performance

The substantial shift in EBITDA from a gain to a significant loss indicates a marked deterioration in Panacea Biotec's operational performance. This change suggests the company may be facing challenges in managing its operating costs effectively or experiencing pressure on its profit margins.

The widening net loss, coupled with declining revenue, points to a challenging quarter for Panacea Biotec. These results may prompt investors and analysts to closely monitor the company's future strategies and performance in the coming quarters.

As the pharmaceutical sector continues to evolve, Panacea Biotec's management may need to address these financial challenges and explore avenues for revenue growth and cost optimization to improve its financial health.

Panacea Biotec , a leading biotechnology company, has reported a significant increase in losses for the quarter ended September 30, 2025, despite a rise in total income. The company's financial results, released on November 14, 2025, reveal a complex picture of growth and challenges.

Financial Highlights

• Net Loss: Panacea Biotec posted a net loss of ₹1,563.00 lakh for Q2 FY2026, compared to a loss of ₹668.00 lakh in the same quarter last year.
• Total Income: The company's total income rose to ₹9,442.00 lakh in Q2 FY2026 from ₹8,005.00 lakh in Q2 FY2025.
• Revenue from Operations: Increased to ₹9,081.00 lakh in Q2 FY2026 from ₹7,664.00 lakh in Q2 FY2025.

Segment Performance

The company's financial results show a mixed performance across its two main segments:

Exceptional Income

During the half-year period ended September 30, 2025, Panacea Biotec recognized exceptional income of ₹1,402.00 lakh, which included:

• ₹858.00 lakh from a settlement agreement with Apotex Inc., USA.
• ₹544.00 lakh from deferred consideration on the sale of domestic pharmaceutical brands.

Management's Perspective

Despite the increased losses, the management remains optimistic about the company's future. They cited several factors supporting their going concern basis:

1. Surplus funds from the sale of pharmaceutical formulations brands in India and Nepal in March 2022.
2. Strengthened working capital position.
3. Setting up new facilities for enhancing vaccine drug substance manufacturing capacities.
4. Scaling up nutrition and pharmaceutical formulations business.
5. Higher long-term business orders for vaccines from key institutional customers.

Looking Ahead

While the widened losses are a concern, Panacea Biotec's increased revenue and exceptional income suggest potential for future growth. The company's focus on expanding its vaccine manufacturing capabilities and diversifying its product portfolio may help in improving its financial performance in the coming quarters.

Investors and stakeholders will be watching closely to see how Panacea Biotec navigates these challenges and capitalizes on its growth initiatives in the biotechnology and pharmaceutical sectors.